Favorable Media Coverage Somewhat Unlikely to Impact Ohr Pharmaceuticals (OHRP) Share Price
Media headlines about Ohr Pharmaceuticals (NASDAQ:OHRP) have trended positive this week, Accern reports. Accern identifies negative and positive news coverage by monitoring more than twenty million blog and news sources in real time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Ohr Pharmaceuticals earned a news impact score of 0.28 on Accern’s scale. Accern also assigned headlines about the biotechnology company an impact score of 46.5367414768538 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the near future.
These are some of the headlines that may have impacted Accern Sentiment Analysis’s scoring:
- SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces an Investigation Concerning Possible Breaches of … – Business Wire (press release) (businesswire.com)
- Ohr Pharmaceutical, Inc. (OHRP) – Watch List stock – Wall Street Morning (wallstreetmorning.com)
- Brokerages Anticipate Ohr Pharmaceuticals, Inc. (OHRP) to Post -$0.07 Earnings Per Share (americanbankingnews.com)
- SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces an Investigation Concerning Possible Breaches of Fiduciary Duty by Certain Officers and Directors of Ohr Pharmaceutical, Inc. (finance.yahoo.com)
- Reviewing Ohr Pharmaceuticals (OHRP) & its Peers (americanbankingnews.com)
Ohr Pharmaceuticals (OHRP) opened at 0.7761 on Thursday. The firm has a 50 day moving average of $0.68 and a 200 day moving average of $0.70. The firm’s market capitalization is $43.63 million. Ohr Pharmaceuticals has a one year low of $0.56 and a one year high of $4.05.
Ohr Pharmaceuticals (NASDAQ:OHRP) last announced its quarterly earnings data on Tuesday, August 8th. The biotechnology company reported ($0.07) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.25) by $0.18. Equities analysts forecast that Ohr Pharmaceuticals will post ($0.39) EPS for the current year.
OHRP has been the topic of several recent research reports. Zacks Investment Research raised shares of Ohr Pharmaceuticals from a “hold” rating to a “buy” rating and set a $0.75 price objective on the stock in a research note on Tuesday, July 18th. HC Wainwright set a $10.00 price objective on shares of Ohr Pharmaceuticals and gave the stock a “buy” rating in a research note on Wednesday, August 16th.
TRADEMARK VIOLATION NOTICE: This news story was originally published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this news story on another site, it was illegally stolen and reposted in violation of U.S. and international trademark & copyright legislation. The legal version of this news story can be accessed at https://www.thecerbatgem.com/2017/09/14/favorable-media-coverage-somewhat-unlikely-to-impact-ohr-pharmaceuticals-ohrp-share-price.html.
Ohr Pharmaceuticals Company Profile
OHR Pharmaceutical, Inc, a pharmaceutical company, focuses on the development of novel therapeutics and delivery technologies for the treatment of ocular disease. Its lead clinical program is topical Squalamine, a small molecule anti-angiogenic drug, which could provide a non-invasive therapy to enhance vision outcomes.
Receive News & Stock Ratings for Ohr Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ohr Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.